122 related articles for article (PubMed ID: 16501923)
1. [Multi-targeting drugs and multi-drug targeting in metastatic renal cell carcinoma. Concept of co-inhibition of the epidermal growth].
Rohde D
Urologe A; 2006 Mar; 45(3):356-8. PubMed ID: 16501923
[No Abstract] [Full Text] [Related]
2. [The introduction of targeted drugs].
Bergmann L; Miller K
Onkologie; 2010; 33 Suppl 1():1. PubMed ID: 20164667
[No Abstract] [Full Text] [Related]
3. Emerging drugs for renal cell carcinoma.
Varella L; Rini BI
Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?
Rini BI; Bukowski RM
Oncology (Williston Park); 2008 Apr; 22(4):388-96; discussion 396, 402-3, 476 passim. PubMed ID: 18472614
[TBL] [Abstract][Full Text] [Related]
5. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
Amato R
Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
[No Abstract] [Full Text] [Related]
6. Systemic therapy for sarcomatoid renal cell carcinoma.
Pagliaro LC; Tannir N; Sircar K; Jonasch E
Expert Rev Anticancer Ther; 2011 Jun; 11(6):913-20. PubMed ID: 21707288
[TBL] [Abstract][Full Text] [Related]
7. Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?
Procopio G; Ratta R; Grassi P
Expert Rev Anticancer Ther; 2016; 16(2):133-5. PubMed ID: 26654053
[No Abstract] [Full Text] [Related]
8. Recent developments in second and third line therapy of metastatic renal cell carcinoma.
Vitale MG; Cartenì G
Expert Rev Anticancer Ther; 2016 May; 16(5):469-71. PubMed ID: 26999490
[No Abstract] [Full Text] [Related]
9. Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia--easier said than done? A case report.
Al-Najjar F; Jarkowski A
J Oncol Pharm Pract; 2011 Dec; 17(4):436-9. PubMed ID: 20847086
[TBL] [Abstract][Full Text] [Related]
10. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
Dutcher J
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
[No Abstract] [Full Text] [Related]
11. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
12. Renal-cell carcinoma.
Vincenzi B; Santini D; Tonini G
N Engl J Med; 2006 Mar; 354(10):1095-6; author reply 1095-6. PubMed ID: 16528812
[No Abstract] [Full Text] [Related]
13. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Harshman L; Srinivas S
Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
[No Abstract] [Full Text] [Related]
14. What is new in kidney cancer?
Kirkali Z
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1753-5. PubMed ID: 19954286
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
16. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
17. Imaging in metastatic renal cell carcinoma.
Griffin N; Gore ME; Sohaib SA
AJR Am J Roentgenol; 2007 Aug; 189(2):360-70. PubMed ID: 17646462
[TBL] [Abstract][Full Text] [Related]
18. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Kahl C; Hilgendorf I; Freund M; Casper J
Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
[No Abstract] [Full Text] [Related]
19. Effective treatment of metastatic renal cell carcinoma with topical imiquimod therapy.
Okino T; Fujioka A; Nakajima H; Tarutani M; Shuin T; Sano S
J Dtsch Dermatol Ges; 2014 Feb; 12(2):155-7. PubMed ID: 24128072
[No Abstract] [Full Text] [Related]
20. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Bamias A
Eur Urol; 2009 Jun; 55(6):1439. PubMed ID: 18950935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
